A retrospective study of anti-PD1 therapy in advanced cancer patients with known autoimmune conditions.
Phase of Trial: Phase IV
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 06 Dec 2016 New trial record
- 11 Oct 2016 Results assessing safety presented at the 41st European Society for Medical Oncology Congress.